ClinicalTrials.gg
CompletedNCT01017731Updated Jun 10, 2015Results posted

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

A Phase 2 interventional study of IMC-1121B and Moxifloxacin in Cancer and Solid Tumor, sponsored by Eli Lilly and Company. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-10.

Sponsored by Eli Lilly and Company · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine if Ramucirumab (IMC-1121B) causes prolongation of the QT/QTc interval in participants with advanced cancer.

Read the detailed description

The primary purpose of this study is to determine if treatment with ramucirumab causes prolongation of the QTc/QT interval in participants with advanced cancer, to assess the safety and tolerability of ramucirumab therapy, and to evaluate the pharmacokinetic (PK) characteristics of ramucirumab

02

Conditions studied

  • Cancer
  • Solid Tumor

Keywords

  • Advanced Solid tumor
  • Antibodies, Monoclonal
  • QTc
  • Metastatic
  • Malignant
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 68 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has documented advanced or malignant cancer of solid tumor origin which has not responded to standard therapy or for which no standard therapy is available
  • The participant has resolution of adverse events from prior anticancer therapies
  • Performance status of 0 to 2
  • The participant is ≥ 18 years of age
  • The participant is able to provide informed written consent and is amenable to compliance with protocol schedules and testing
  • The participant has adequate liver, kidney, blood, and blood clotting functions as defined in trial entrance criteria
  • The participant agrees to use adequate during the study period and for 8 weeks after the last dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • The participant had anticancer therapy within 14 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
  • The participant had therapeutic radiotherapy within 14 days prior to entering the study
  • The participant has ongoing side effects ≥ Grade 2 due to prior anticancer therapy
  • The participant has brain or
  • The participant has a history of uncontrolled or severe cardiac disease
  • The participant has a history of severe congestive heart failure (CHF)
  • The participant has a known history of arterial thrombotic events
  • The participant has a known history of significant peripheral arterial disease (PAD)
  • The participant has an implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
  • The participant has a history of risk factors for ventricular tachycardia or Torsades de pointes (TdP) [for example, family history (parents or siblings) of long syndrome], history of fainting, unexplained loss of consciousness, or convulsions
  • The participant has a systolic blood pressure (SBP) of > 150 millimeters of mercury (mmHg) or \< 90 mmHg or a diastolic blood pressure (DBP) of \< 45 or > 95 mmHg. (Participants with a history of hypertension who are receiving antihypertensive therapy are permitted on study provided blood pressure is within the parameters detailed above)
  • The participant has a heart rate \< 50 beats per minute (bpm) or > 100 bpm at rest
  • The participant has a abnormality on the , preventing an accurate measurement of the QT interval
  • The participant is using a medication that is known to prolong the ECG QT interval
  • The participant has a known allergy to any of the treatment components including fluoroquinolone antibiotics
  • The participant has received an new drug or device within 14 days prior to enrollment into this study (excluding placement of an intravenous access device)
  • The participant has undergone major surgery within 28 days prior to enrollment
  • The participant has known (HIV) infection
  • The participant, if female, is pregnant or lactating
  • The participant is receiving chronic daily treatment with aspirin [> 325 milligrams per day (mg/day)]
  • The participant has a concurrent active other than adequately treated nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm
  • The participant has psychological, familial, sociological, or geographical conditions which do not permit adequate study follow-up, compliance with the protocol, or signature of
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    IMC-1121B

    Active-control participants (first 16 participants) will receive one dose of moxifloxacin orally 7 days before the first treatment with ramucirumab. All participants will undergo triplicate electrocardiogram (ECG) tests (consisting of three individual ECGs performed consecutively within a period of 4 minutes) and vital signs at various times over the trial period. For Cycle 1, all participants will also receive 2 infusions of diphenhydramine before ramucirumab therapy (the first infusion is 1 day before therapy and the second infusion is 15 minutes before therapy). For Cycles 2, 3, and 4, all participants will receive diphenhydramine 15 minutes before ramucirumab therapy. For Cycle 5 and beyond, diphenhydramine infusions before ramucirumab therapy are at the investigator's discretion. Ramucirumab \[10 milligrams per kilogram (mg/kg)\] intravenously over 60 minutes, once every 3 weeks for minimum of 9 weeks without a break in between.

    Biological: IMC-1121B · Drug: Moxifloxacin · Drug: Diphenhydramine

Interventions

  • BiologicalIMC-1121B

    IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.

    Also known as: Ramucirumab, LY3009806

  • Administered orally

  • Administered IV

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants

    All electrocardiogram (ECG) tests were performed in triplicate prior to ramucirumab treatment. QT is the interval between the Q and T waves and QTc is the QT corrected for heart rate using Fridericia's formula: QTc = QT/RR\^0.33 where RR is the interval between 2 R waves. Each participant's mean QT/QTc value was calculated for each ECG test during Cycle 3 and compared to his/her mean pretreatment QT/QTc value. The greatest change from baseline during Cycle 3 was reported. QTc prolongation is defined as a QTc exceeding 10 milliseconds (msec) with a lower 90% confidence interval (CI) exceeding 5 msec at any postdose time points per the International Conference on Harmonization (ICH) E14 guidelines for non-thorough QT studies (ICH 2005; ICH 2008). Least squares (LS) mean was calculated using a linear mixed model for repeated measures (MMRM) and adjusted for serum concentration.

    Time frame: Baseline, Cycle 3 (1 cycle=21 days)

Secondary outcomes

  1. Number of Participants With Drug-Related Adverse Events (AEs)

    Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to ramucirumab. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: Baseline up to data cut off (approximately 105.6 weeks)

  2. Maximum Concentration (Cmax) During Cycle 1

    Maximum observed concentration of IMC-1121B (ramucirumab) in serum during Cycle 1 (1 cycle=21 days).

    Time frame: Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]

  3. Maximum Concentration (Cmax) During Cycle 1, Day 4

    Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.

    Time frame: Approximately Week 1 (Cycle 1, Day 4)

  4. Maximum Concentration (Cmax) During Cycle 1, Day 8

    Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.

    Time frame: Approximately Week 2 (Cycle 1, Day 8)

  5. Maximum Concentration (Cmax) During Cycle 1, Day 15

    Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.

    Time frame: Approximately Week 3 (Cycle 1, Day 15)

  6. Maximum Concentration (Cmax) During Cycle 2

    Cmax was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.

    Time frame: Cycle 2 (predose and 1.25 hours postdose)

  7. Maximum Concentration (Cmax) During Cycle 3

    The maximum observed serum concentration of IMC-1121B (ramucirumab) at steady state (Cmax,ss) during Cycle 3 (1 cycle=21 days).

    Time frame: Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]

  8. Area Under Concentration (AUC) During Cycle 1

    The area under the concentration versus time curve from time 0 to infinity \[AUC(0-inf)\] is reported during Cycle 1 (1 cycle=21 days).

    Time frame: Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]

  9. Area Under Concentration (AUC) During Cycle 1, Day 4

    AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).

    Time frame: Approximately Week 1 (Cycle 1, Day 4)

  10. Area Under Concentration (AUC) During Cycle 1, Day 8

    AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).

    Time frame: Approximately Week 2 (Cycle 1, Day 8)

  11. Area Under Concentration (AUC) During Cycle 1, Day 15

    AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).

    Time frame: Approximately Week 3 (Cycle 1, Day 15)

  12. Area Under Concentration (AUC) During Cycle 2, Day 1

    AUC was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.

    Time frame: Approximately Week 1 (Cycle 2, Day 1)

  13. Area Under Concentration (AUC) During Cycle 3

    The area under the concentration versus time curve over the dosing interval at steady state \[AUC(tau,ss)\] is reported during Cycle 3 (1 cycle=21 days).

    Time frame: Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]

07

Results

Posted Jun 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneIMC-1121B (Ramucirumab)
Started68
Received at least 1 dose of study drug66
Completed60
Not completed8
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject3
Withdrew: Physician decision2
Withdrew: Adverse event1

Outcome measures

PrimaryChange From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants

All electrocardiogram (ECG) tests were performed in triplicate prior to ramucirumab treatment. QT is the interval between the Q and T waves and QTc is the QT corrected for heart rate using Fridericia's formula: QTc = QT/RR\^0.33 where RR is the interval between 2 R waves. Each participant's mean QT/QTc value was calculated for each ECG test during Cycle 3 and compared to his/her mean pretreatment QT/QTc value. The greatest change from baseline during Cycle 3 was reported. QTc prolongation is defined as a QTc exceeding 10 milliseconds (msec) with a lower 90% confidence interval (CI) exceeding 5 msec at any postdose time points per the International Conference on Harmonization (ICH) E14 guidelines for non-thorough QT studies (ICH 2005; ICH 2008). Least squares (LS) mean was calculated using a linear mixed model for repeated measures (MMRM) and adjusted for serum concentration.

Time frame:
Baseline, Cycle 3 (1 cycle=21 days)
Reported as:
Least squares mean · milliseconds (msec)
Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants
milliseconds (msec)IMC-1121B (Ramucirumab)
Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants3.9132 (1.2880 to 6.5385)
Statistical analysis
  • IMC-1121B (Ramucirumab) · Mixed Models Analysis · p = 0.0161 (The p-value for QTc interval prolongation compared to baseline.)
SecondaryNumber of Participants With Drug-Related Adverse Events (AEs)

Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to ramucirumab. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
Baseline up to data cut off (approximately 105.6 weeks)
Reported as:
Number · participants
Number of Participants With Drug-Related Adverse Events (AEs)
participantsIMC-1121B (Ramucirumab)
Related TEAE42
Related SAE11
Related Grade 3 or higher TEAE14
Related AE leading to discontinuation6
SecondaryMaximum Concentration (Cmax) During Cycle 1

Maximum observed concentration of IMC-1121B (ramucirumab) in serum during Cycle 1 (1 cycle=21 days).

Time frame:
Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]
Reported as:
Geometric mean · micrograms per milliliter (mcg/mL)
Maximum Concentration (Cmax) During Cycle 1
micrograms per milliliter (mcg/mL)IMC-1121B (Ramucirumab)
Maximum Concentration (Cmax) During Cycle 1485 ± 43
SecondaryMaximum Concentration (Cmax) During Cycle 1, Day 4

Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.

Time frame:
Approximately Week 1 (Cycle 1, Day 4)

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) During Cycle 1, Day 8

Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.

Time frame:
Approximately Week 2 (Cycle 1, Day 8)

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) During Cycle 1, Day 15

Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.

Time frame:
Approximately Week 3 (Cycle 1, Day 15)

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) During Cycle 2

Cmax was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.

Time frame:
Cycle 2 (predose and 1.25 hours postdose)

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) During Cycle 3

The maximum observed serum concentration of IMC-1121B (ramucirumab) at steady state (Cmax,ss) during Cycle 3 (1 cycle=21 days).

Time frame:
Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]
Reported as:
Geometric mean · micrograms per milliliter (mcg/mL)
Maximum Concentration (Cmax) During Cycle 3
micrograms per milliliter (mcg/mL)IMC-1121B (Ramucirumab)
Maximum Concentration (Cmax) During Cycle 3571 ± 41
SecondaryArea Under Concentration (AUC) During Cycle 1

The area under the concentration versus time curve from time 0 to infinity \[AUC(0-inf)\] is reported during Cycle 1 (1 cycle=21 days).

Time frame:
Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]
Reported as:
Geometric mean · hours*micrograms/milliliter (h*mcg/mL)
Area Under Concentration (AUC) During Cycle 1
hours*micrograms/milliliter (h*mcg/mL)IMC-1121B (Ramucirumab)
Area Under Concentration (AUC) During Cycle 167400 ± 38
SecondaryArea Under Concentration (AUC) During Cycle 1, Day 4

AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).

Time frame:
Approximately Week 1 (Cycle 1, Day 4)

No measurements were reported for this outcome.

SecondaryArea Under Concentration (AUC) During Cycle 1, Day 8

AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).

Time frame:
Approximately Week 2 (Cycle 1, Day 8)

No measurements were reported for this outcome.

SecondaryArea Under Concentration (AUC) During Cycle 1, Day 15

AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).

Time frame:
Approximately Week 3 (Cycle 1, Day 15)

No measurements were reported for this outcome.

SecondaryArea Under Concentration (AUC) During Cycle 2, Day 1

AUC was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.

Time frame:
Approximately Week 1 (Cycle 2, Day 1)

No measurements were reported for this outcome.

SecondaryArea Under Concentration (AUC) During Cycle 3

The area under the concentration versus time curve over the dosing interval at steady state \[AUC(tau,ss)\] is reported during Cycle 3 (1 cycle=21 days).

Time frame:
Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]
Reported as:
Geometric mean · hours*micrograms/milliliter (h*mcg/mL)
Area Under Concentration (AUC) During Cycle 3
hours*micrograms/milliliter (h*mcg/mL)IMC-1121B (Ramucirumab)
Area Under Concentration (AUC) During Cycle 369900 ± 41

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IMC-1121B (Ramucirumab)—32/66 (48.5%)61/66 (92.4%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventIMC-1121B (Ramucirumab)
Disease progressionGeneral disorders6/66
DyspnoeaRespiratory, thoracic and mediastinal disorders6/66
Abdominal painGastrointestinal disorders4/66
DehydrationMetabolism and nutrition disorders4/66
Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/66
NauseaGastrointestinal disorders2/66
VomitingGastrointestinal disorders2/66
HyponatraemiaMetabolism and nutrition disorders2/66
Pleural effusionRespiratory, thoracic and mediastinal disorders2/66
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/66
Most frequent other events
Showing 10 of 40
Most frequent other events
EventIMC-1121B (Ramucirumab)
Decreased appetiteMetabolism and nutrition disorders22/66
NauseaGastrointestinal disorders21/66
FatigueGeneral disorders21/66
HeadacheNervous system disorders20/66
DyspnoeaRespiratory, thoracic and mediastinal disorders18/66
Abdominal painGastrointestinal disorders16/66
DiarrhoeaGastrointestinal disorders16/66
VomitingGastrointestinal disorders16/66
CoughRespiratory, thoracic and mediastinal disorders14/66
Oedema peripheralGeneral disorders11/66

Baseline characteristics

Safety population: Participants who received any quantity of ramucirumab, regardless of their eligibility for the study.

Age, Customized
Age, Customized(participants)IMC-1121B (Ramucirumab)
Between 18 and 65 years40
>=65 years26
Sex: Female, Male
Sex: Female, Male(Participants)IMC-1121B (Ramucirumab)
Female30
Male36
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)IMC-1121B (Ramucirumab)
White60
Black5
Asian1
Region of Enrollment
Region of Enrollment(participants)IMC-1121B (Ramucirumab)
United States66
Ethnicity
Ethnicity(participants)IMC-1121B (Ramucirumab)
Hispanic or Latino4
Non-Hispanic or Latino62
08

Study locations

7 sites
  • ImClone Investigational Site
    Atlanta, Georgia 30322, United States
  • ImClone Investigational Site
    Metairie, Louisiana 70006, United States
  • ImClone Investigational Site
    Ann Arbor, Michigan 48109, United States
  • ImClone Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • ImClone Investigational Site
    Providence, Rhode Island 02903, United States
  • ImClone Investigational Site
    Houston, Texas 77024, United States
  • ImClone Investigational Site
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Olszanski AJ, Smith DC, Camacho LH, Thompson J, Ramalingam SS, Harvey RD, Campos L, Ferry D, Tang S, Gao L, Safran H. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. Oncologist. 2016 Apr;21(4):402-3. doi: 10.1634/theoncologist.2015-0467. Epub 2016 Mar 16. PubMed 26984445 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Apr 2010 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 4 years 2 months after primary completion. A results delay was requested in Jul 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2009
First posted
Nov 23, 2009
Start
Nov 2009
Primary completionActual
Apr 2010
CompletionActual
May 2014
Results delay requested
Jul 29, 2010
Results first posted
Jun 18, 2014
Last update
Jun 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01017731
Responsible party
Sponsor
First posted
Nov 23, 2009
Start date
Nov 2009
Primary completion
Apr 2010
Completion
May 2014
Results posted
Jun 18, 2014
Last update
Jun 10, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion